Related Experiment Video
Updated: Oct 31, 2025
Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
Understanding the Relationship between Breast Reconstruction Subtype and Risk of Financial Toxicity: A
Chad M Bailey1, Malke Asaad1, Stefanos Boukovalas1
1From Proliance Surgeons; the Departments of Plastic and Reconstructive Surgery and Health Services Research, University of Texas M. D. Anderson Cancer Center; the University of Texas Houston McGovern Medical School; and the Baker Institute for Public Policy, Rice University.
Breast reconstruction type does not affect financial toxicity risk. Higher income and supplemental insurance protect against costs, while radiation therapy worsens financial toxicity for breast cancer patients.
Area of Science:
- Oncology
- Health Economics
- Surgical Oncology
Background:
- Financial toxicity is an understudied consequence of breast reconstruction.
- Understanding the financial burden associated with different breast reconstruction methods is crucial.
Purpose of the Study:
- To examine the association between breast reconstruction subtypes and financial toxicity.
- To identify factors influencing financial toxicity in breast cancer patients undergoing reconstruction.
Main Methods:
- Cross-sectional survey of 350 female breast cancer patients undergoing reconstruction.
- Utilized the Comprehensive Score for Financial Toxicity instrument.
- Performed multivariable linear regression to analyze associations.
Main Results:
- No significant difference in financial toxicity risk was found across oncoplastic, implant-based, or autologous reconstruction subtypes.
- Supplemental insurance and annual household income over $40,000 were protective against financial toxicity.
- Radiation therapy was associated with increased financial toxicity.
Conclusions:
- Breast reconstruction subtype does not influence financial toxicity.
- Financial toxicity in breast cancer patients is mitigated by higher income and supplemental insurance.
- Further research is needed to identify key cost drivers in breast cancer care.
